Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial

Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for refractory recurrent/metastatic nasopharyngeal carcinoma (RM-NPC). We conducted a phase 2 trial to evaluate the safety and activity of camrelizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Li, Jia, Guo-Dong, Lv, Xiao-Fei, Xie, Si-Yi, Guo, Shan-Shan, Lin, Da-Feng, Liu, Li-Ting, Luo, Dong-Hua, Li, Yi-Fu, Deng, Shen-Wen, Guo, Ling, Zeng, Mu-Sheng, Cai, Xiu-Yu, Liu, Sai-Lan, Sun, Xue-Song, Li, Xiao-Yun, Li, Su-Chen, Chen, Qiu-Yan, Tang, Lin-Quan, Mai, Hai-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425437/
https://www.ncbi.nlm.nih.gov/pubmed/37580352
http://dx.doi.org/10.1038/s41467-023-40402-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425437/
https://www.ncbi.nlm.nih.gov/pubmed/37580352
http://dx.doi.org/10.1038/s41467-023-40402-x

Ejemplares similares